Wall Street Zen Upgrades Dominari (NASDAQ:DOMH) to "Buy"

Key Points

• Dominari Holdings Inc. (NASDAQ:DOMH) has been upgraded from a "sell" to a "buy" rating by Wall Street Zen, reflecting improved investor sentiment.
• The company's stock is currently priced at $6.40, with a market capitalization of approximately $98.43 million and notable fluctuations in its 12-month trading range.
• Dominari focuses on developing small-molecule anticancer therapies, including treatment candidates for various forms of cancer, highlighting its role within the biotechnology sector.

Dominari (NASDAQ:DOMH - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "buy" rating in a research report issued on Saturday.

Dominari Price Performance

Shares of DOMH traded up $0.02 during mid-day trading on Friday, reaching $5.56. The company had a trading volume of 325,595 shares, compared to its average volume of 408,298. Dominari has a twelve month low of $0.83 and a twelve month high of $13.58. The company's 50-day moving average is $5.41 and its 200-day moving average is $5.44. The company has a market capitalization of $85.51 million, a P/E ratio of -2.35 and a beta of 0.50.

Dominari (NASDAQ:DOMH - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter. Dominari had a negative return on equity of 94.32% and a negative net margin of 36.01%.The company had revenue of $34.10 million during the quarter.

Institutional Investors Weigh In On Dominari

A number of hedge funds and other institutional investors have recently bought and sold shares of DOMH. Renaissance Technologies LLC increased its holdings in Dominari by 20.0% during the 4th quarter. Renaissance Technologies LLC now owns 56,326 shares of the company's stock valued at $55,000 after purchasing an additional 9,400 shares in the last quarter. Magnus Financial Group LLC acquired a new stake in Dominari during the 2nd quarter valued at $136,000. Jane Street Group LLC acquired a new stake in Dominari during the 2nd quarter valued at $158,000. Geode Capital Management LLC increased its holdings in Dominari by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock valued at $361,000 after purchasing an additional 1,866 shares in the last quarter. Finally, PFG Investments LLC acquired a new stake in Dominari during the 1st quarter valued at $566,000. 42.48% of the stock is owned by institutional investors and hedge funds.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.